Developer docs
API playgroundTry for free, no card

Search company profiles

MatriSys Bioscience

Full company profile

uuid00038kg

Namestring
MatriSys Bioscience
Legal namestring
MatriSys Bioscience, Inc.
Websiteurl
matrisysbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

MatriSys Bioscience, Inc. is a privately held, clinical-stage specialty biopharmaceutical company founded in 2015 and based in La Jolla, California, with 1–10 employees. The company is developing a novel class of topical bacteriotherapy products derived from beneficial bacteria isolated from the healthy human skin microbiome, targeting chronic inflammatory skin diseases characterized by microbiome dysbiosis, including atopic dermatitis, acne, Netherton syndrome, and solar/actinic keratoses. Its discovery platform is built on research from the Gallo Laboratory at the University of California San Diego and screens thousands of skin microbes to identify and optimize bacterial strains with defined mechanisms of action, such as the production of lantibiotics that directly kill Staphylococcus aureus.

The company's lead clinical program, MSB-0221, is a topical prescription formulation designed to treat atopic dermatitis via a triple mechanism: antimicrobial activity through lantibiotic production, inhibition of damaging proteases and phenol-soluble modulins via autoinducing peptide (AIP) signaling, and restoration of commensal skin bacteria to prevent recurrent S. aureus colonization. The broader pipeline targets approximately 230 million+ patients globally with dermatological conditions, with a stated goal of reducing reliance on steroids, immunosuppressants, and antibiotics that carry well-known safety and resistance concerns. Scientific founder Rich Gallo, MD, PhD, is a Distinguished Professor and Founding Chairman of Dermatology at UCSD and is credited with discovering antimicrobial peptides in mammalian skin.

Commercially, MatriSys is pre-revenue with no marketed products, no disclosed pricing, and no distribution or payer relationships in the input data. Revenue mechanics will depend on either out-licensing to a larger dermatology commercial player or building a specialty dermatology commercial organization post-approval, with the CEO's prior pharma-exit track record (Agouron→Pfizer, Ardea→AstraZeneca) and the addition of a Chief Business Officer pointing toward a partnering-oriented go-to-market. The company has raised approximately $4.5M in disclosed funding across 2017 and 2021, with additional participation from Mesa Verde Venture Partners and Baker & Eastlack Ventures.

Short descriptiontext

MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical bacteriotherapy products from beneficial skin bacteria to treat chronic inflammatory skin diseases such as atopic dermatitis, acne, Netherton syndrome, and solar keratosis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
skin microbiome therapeutics, topical bacteriotherapy, atopic dermatitis treatment, live biopharmaceutical products, dermatology drug development
Industry2 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAG
Sensitive Skin & Barrier Repair
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Dermatology Biopharmaceuticals
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical prescription bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. Its lead program MSB-0221 targets atopic dermatitis by killing Staphylococcus aureus and restoring skin homeostasis, with additional pipeline programs for acne, Netherton syndrome, and solar keratosis. All candidates leverage a UCSD Gallo Laboratory-derived discovery platform that screens and optimizes commensal skin strains into topical formulations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

MatriSys Bioscience is a biopharmaceutical company developing a novel class of bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. The company's lead product is MSB-0221, a clinical-stage program for Atopic Dermatitis treatment. The broader pipeline includes therapeutic candidates for Acne, Netherton Syndrome, and Solar Keratosis. All programs are built on a discovery platform that screens and optimizes beneficial bacteria strains for topical prescription formulations that restore skin homeostasis and combat microbiome dysbiosis.

Product and service5 records
1MSB-0221
CategoryClinical-stage dermatology biopharmaceutical
Description

Topical prescription bacteriotherapy for Atopic Dermatitis (AD) that uses beneficial bacteria to restore the commensal skin microbiome, kill or inhibit Staphylococcus aureus, inhibit aggressive proteases and PSMs, and improve skin immune and barrier dysfunction without the skin-thinning and safety liabilities of steroids or immunosuppressants.

2Bacteriotherapy Discovery Platform
CategoryMicrobiome drug discovery platform
Description

Skin microbiome discovery platform, rooted in UCSD Gallo Laboratory research, that screens thousands of microbes on the skin to identify beneficial bacteria that can treat skin disorders and then optimizes selected strains for clinical development of topical prescription formulations.

3Acne Bacteriotherapy Program
CategoryClinical-stage dermatology biopharmaceutical
Description

Topical bacteriotherapy program targeting acne by using the healthy skin microbiome to control Cutibacterium acnes and modulate innate and adaptive immune homeostasis, as an alternative to antibiotic-based acne therapies.

4Netherton Syndrome Bacteriotherapy Program
CategoryClinical-stage dermatology biopharmaceutical (rare disease)
Description

Pipeline program that applies microbiome-targeting technology derived from skin-barrier-microbiome interaction studies to address microbiome abnormalities associated with severity of Netherton Syndrome (SPINK5 mutation).

5Solar Keratosis Bacteriotherapy Program
CategoryClinical-stage dermatology biopharmaceutical
Description

Pipeline bacteriotherapy program targeting Solar Keratosis / Actinic Keratoses as a non-surgical treatment alternative to Mohs surgery for the removal of affected areas.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MatriSys Bioscience

Dermatology Biopharmaceuticalsmatrisysbio.com

MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical bacteriotherapy products from beneficial skin bacteria to treat chronic inflammatory skin diseases such as atopic dermatitis, acne, Netherton syndrome, and solar keratosis.

What MatriSys Bioscience does

MatriSys Bioscience, Inc. is a privately held, clinical-stage specialty biopharmaceutical company founded in 2015 and based in La Jolla, California, with 1–10 employees. The company is developing a novel class of topical bacteriotherapy products derived from beneficial bacteria isolated from the healthy human skin microbiome, targeting chronic inflammatory skin diseases characterized by microbiome dysbiosis, including atopic dermatitis, acne, Netherton syndrome, and solar/actinic keratoses. Its discovery platform is built on research from the Gallo Laboratory at the University of California San Diego and screens thousands of skin microbes to identify and optimize bacterial strains with defined mechanisms of action, such as the production of lantibiotics that directly kill Staphylococcus aureus.

The company's lead clinical program, MSB-0221, is a topical prescription formulation designed to treat atopic dermatitis via a triple mechanism: antimicrobial activity through lantibiotic production, inhibition of damaging proteases and phenol-soluble modulins via autoinducing peptide (AIP) signaling, and restoration of commensal skin bacteria to prevent recurrent S. aureus colonization. The broader pipeline targets approximately 230 million+ patients globally with dermatological conditions, with a stated goal of reducing reliance on steroids, immunosuppressants, and antibiotics that carry well-known safety and resistance concerns. Scientific founder Rich Gallo, MD, PhD, is a Distinguished Professor and Founding Chairman of Dermatology at UCSD and is credited with discovering antimicrobial peptides in mammalian skin.

Commercially, MatriSys is pre-revenue with no marketed products, no disclosed pricing, and no distribution or payer relationships in the input data. Revenue mechanics will depend on either out-licensing to a larger dermatology commercial player or building a specialty dermatology commercial organization post-approval, with the CEO's prior pharma-exit track record (Agouron→Pfizer, Ardea→AstraZeneca) and the addition of a Chief Business Officer pointing toward a partnering-oriented go-to-market. The company has raised approximately $4.5M in disclosed funding across 2017 and 2021, with additional participation from Mesa Verde Venture Partners and Baker & Eastlack Ventures.

MatriSys Bioscience firmographics

Firmographics
Name
MatriSys Bioscience
Legal name
MatriSys Bioscience, Inc.
Website
https://matrisysbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical bacteriotherapy products from beneficial skin bacteria to treat chronic inflammatory skin diseases such as atopic dermatitis, acne, Netherton syndrome, and solar keratosis.
Ownership category
akta.pro rank

MatriSys Bioscience industry classification

Industry
Product category
Dermatology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYCRABAAAG
Sensitive Skin & Barrier Repair

Keywords

  • Skin microbiome therapeutics
  • Topical bacteriotherapy
  • Atopic dermatitis treatment
  • Live biopharmaceutical products
  • Dermatology drug development

Where MatriSys Bioscience is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Markets served

MatriSys Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

MatriSys Bioscience product offering

Product offering

Core offering

MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical prescription bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. Its lead program MSB-0221 targets atopic dermatitis by killing Staphylococcus aureus and restoring skin homeostasis, with additional pipeline programs for acne, Netherton syndrome, and solar keratosis. All candidates leverage a UCSD Gallo Laboratory-derived discovery platform that screens and optimizes commensal skin strains into topical formulations.

Product overview

MatriSys Bioscience is a biopharmaceutical company developing a novel class of bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. The company's lead product is MSB-0221, a clinical-stage program for Atopic Dermatitis treatment. The broader pipeline includes therapeutic candidates for Acne, Netherton Syndrome, and Solar Keratosis. All programs are built on a discovery platform that screens and optimizes beneficial bacteria strains for topical prescription formulations that restore skin homeostasis and combat microbiome dysbiosis.

Differentiator

Problem solved

Functional benefit

Products and services

  • MSB-0221 Topical prescription bacteriotherapy for Atopic Dermatitis (AD) that uses beneficial bacteria to restore the commensal skin microbiome, kill or inhibit Staphylococcus aureus, inhibit aggressive proteases and PSMs, and improve skin immune and barrier dysfunction without the skin-thinning and safety liabilities of steroids or immunosuppressants.
  • Bacteriotherapy Discovery Platform Skin microbiome discovery platform, rooted in UCSD Gallo Laboratory research, that screens thousands of microbes on the skin to identify beneficial bacteria that can treat skin disorders and then optimizes selected strains for clinical development of topical prescription formulations.
  • Acne Bacteriotherapy Program Topical bacteriotherapy program targeting acne by using the healthy skin microbiome to control Cutibacterium acnes and modulate innate and adaptive immune homeostasis, as an alternative to antibiotic-based acne therapies.
  • Netherton Syndrome Bacteriotherapy Program Pipeline program that applies microbiome-targeting technology derived from skin-barrier-microbiome interaction studies to address microbiome abnormalities associated with severity of Netherton Syndrome (SPINK5 mutation).
  • Solar Keratosis Bacteriotherapy Program Pipeline bacteriotherapy program targeting Solar Keratosis / Actinic Keratoses as a non-surgical treatment alternative to Mohs surgery for the removal of affected areas.

Companies that use MatriSys Bioscience

Customer profile

Segments4 records

Ideal customer profiles1 record

MatriSys Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MatriSys Bioscience partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

MatriSys Bioscience competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MatriSys Bioscience social profiles

Digital presence

MatriSys Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MatriSys Bioscience leadership team

Management profile

Number of profiles

Profiles6 records

MatriSys Bioscience funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MatriSys Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MatriSys Bioscience

What does MatriSys Bioscience do?

MatriSys Bioscience is a clinical-stage biopharmaceutical company developing topical prescription bacteriotherapy products derived from beneficial bacteria of the healthy human skin microbiome. Its lead program MSB-0221 targets atopic dermatitis by killing Staphylococcus aureus and restoring skin homeostasis, with additional pipeline programs for acne, Netherton syndrome, and solar keratosis. All candidates leverage a UCSD Gallo Laboratory-derived discovery platform that screens and optimizes commensal skin strains into topical formulations.

Is MatriSys Bioscience a public or private company?

MatriSys Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was MatriSys Bioscience founded?

MatriSys Bioscience was founded in 2015. It employs 1 to 10 people.

Where is MatriSys Bioscience based?

MatriSys Bioscience is headquartered in La Jolla, United States, in the North America region.

Does MatriSys Bioscience have an API?

No public API is recorded for MatriSys Bioscience.

What industry is MatriSys Bioscience in?

MatriSys Bioscience's product category is Dermatology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of CRABAAAG, Sensitive Skin & Barrier Repair. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMatriSys Bioscience Announces Corporate and Strategic UpdateMatriSys Bioscience, a private clinical-stage pharmaceutical company focused on live biotherapeutic products for dermatologic diseases, provided a progress update on its three lead programs including MSB-0221 for Atopic Dermatitis, MSB-3163 for Acne, and MSB-2040 for Netherton's Syndrome. The company reported that MSB-0221 is ready for Phase 2 proof-of-concept study initiation in 2023, MSB-3163 has over 75% enrollment in its Phase 1b study with results expected in H1 2023, and regulatory applications for orphan designation are being filed for MSB-2040. The CEO indicated the company will execute on its plans following a Series A raise, supported by a growing IP estate of six issued US patents.openPR.comGlobal Microbiome Cosmetics Market | Key Players are GALLINEE, MATRISYS BIOSCIENCE, Glowbiotics, Inc., Quorum Innovations, Siolta Therapeutics, Revlon, The Estee Lauder Companies Inc., and Yakult HonsThe global microbiome cosmetics market is projected to grow at a CAGR of 29.15% during the forecast period. Asia Pacific is expected to lead global consumption, with China, India, and South Korea as key revenue-generating countries. The market is driven by rising demand for probiotic skincare and technological advancements.GlobeNewswireMatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-resistant S. pseudintermediusMatriSys Bioscience published research on a feline-derived Staphylococcus felis strain that inhibits drug-resistant Staphylococcus pseudintermedius. The study showed the strain reduced MRSP skin colonization in mice and disrupted bacterial membranes. The findings support using beneficial bacteria for treating difficult-to-treat skin infections.GlobeNewswireMatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology SummitMatriSys Bioscience CEO Philippe Calais will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, held virtually August 3-5, 2021. The presentation, titled 'Developing Beneficial Bacteria as Topical Therapeutics to Treat Skin Diseases,' will occur on Wednesday, August 4, 2021, in the session 'Advancing Clinical Development of Live Biotherapeutics.'GlobeNewswireMatriSys Bioscience Names Joyce Rico as Chief Medical OfficerMatriSys Bioscience appointed Joyce Rico as Chief Medical Officer, bringing over 20 years of experience in dermatology drug development and regulatory strategy. The company's technology harnesses beneficial bacteria to treat inflammatory skin diseases, with a lead program in atopic dermatitis and advancing therapeutics for acne and rosacea.GlobeNewswireMatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne TreatmentMatriSys Bioscience licensed compound MSB-3163 from UCSD's Dr. Richard Gallo's lab to develop an acne treatment. The compound, derived from Staphylococcus capitis, showed potency greater than common acne antibiotics in preclinical models. MatriSys plans a first-in-human proof-of-concept clinical trial.GlobeNewswireMatriSys Bioscience Raises more than $3 million to Advance its Portfolio of Products to Treat Inflammatory Skin DiseasesMatriSys Bioscience raised more than $3 million in an oversubscribed bridge financing led by existing and new investors. The company will use the proceeds to advance its lead programs harnessing beneficial bacteria to treat inflammatory skin diseases and build its management team.PR NewswireInsights on the Netherton Syndrome Global Market (2020 to 2027) - by Epidemiology, Therapy and GeographyResearchAndMarkets.com published a global market forecast report for Netherton Syndrome, projecting the market to grow from $19.57 million in 2019 to $74.31 million by 2027, representing a compound annual growth rate of 20.3%. The report segments the market by therapy type, with keratolytic agents holding the largest share in 2019 while biological therapies are expected to register the highest growth rate through 2027. The report identifies Lifemax Laboratories, Azitra, Sixera Pharma, Dermelix Biotherapeutics, Matrisys Bioscience, Quoin Pharmaceuticals, and Krystal Biotech as leading companies operating in this rare disease market.GlobeNewswireMatriSys Bioscience is pleased to announce the appointmentMatriSys Bioscience appointed Dr. James Mackay to its Board of Directors. Mackay brings over 30 years of pharmaceutical development experience, including leading the $1.2B Ardea Biosciences acquisition and serving as CEO of Aristea Therapeutics. He will support the company's Phase 2 clinical development of its lead program.GlobeNewswireMatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of DirectorsMatriSys Bioscience appointed Jennifer Giottonini Cayer to its board of directors. She brings over 25 years of life science leadership, including co-founding venture-funded biotech companies and executing alliances worth over $5 billion. The company will benefit from her experience as it advances clinical development of its microbiome-based therapies.